Next Article in Journal
Tacrolimus Modulates TGF-β Signaling to Induce Epithelial-Mesenchymal Transition in Human Renal Proximal Tubule Epithelial Cells
Next Article in Special Issue
Managing Status Epilepticus in the Older Adult
Previous Article in Journal
Long-Term Weight Change after Initiating Second-Generation Antidepressants
Previous Article in Special Issue
Management of Status Epilepticus in Children
Open AccessReview

Treatment of Established Status Epilepticus

Department of Neurology, Rush University Medical Center, 1725 West Harrison Street, Suite 885, Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Gretchen M. Brophy and Paul M. Vespa
J. Clin. Med. 2016, 5(5), 49; https://doi.org/10.3390/jcm5050049
Received: 1 February 2016 / Revised: 29 March 2016 / Accepted: 19 April 2016 / Published: 25 April 2016
(This article belongs to the Special Issue Understanding and Treatment of Status Epilepticus)
Status epilepticus is the most severe form of epilepsy, with a high mortality rate and high health care costs. Status epilepticus is divided into four stages: early, established, refractory, and super-refractory. While initial treatment with benzodiazepines has become standard of care for early status epilepticus, treatment after benzodiazepine failure (established status epilepticus (ESE)) is incompletely studied. Effective treatment of ESE is critical as morbidity and mortality increases dramatically the longer convulsive status epilepticus persists. Phenytoin/fosphenytoin, valproic acid, levetiracetam, phenobarbital, and lacosamide are the most frequently prescribed antiseizure medications for treatment of ESE. To date there are no class 1 data to support pharmacologic recommendations of one agent over another. We review each of these medications, their pharmacology, the scientific evidence in support and against each in the available literature, adverse effects and safety profiles, dosing recommendations, and limitations of the available evidence. We also discuss future directions including the established status epilepticus treatment trial (ESETT). Substantial further research is urgently needed to identify these patients (particularly those with non-convulsive status epilepticus), elucidate the most efficacious antiseizure treatment with head-to-head randomized prospective trials, and determine whether this differs for convulsive vs. non-convulsive ESE. View Full-Text
Keywords: status epilepticus; established status epilepticus; treatment; antiseizure; phenytoin; levetiracetam; valproic acid; phenobarbital; lacosamide status epilepticus; established status epilepticus; treatment; antiseizure; phenytoin; levetiracetam; valproic acid; phenobarbital; lacosamide
Show Figures

Figure 1

MDPI and ACS Style

Falco-Walter, J.J.; Bleck, T. Treatment of Established Status Epilepticus. J. Clin. Med. 2016, 5, 49.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop